ZLAB Zai Lab Ltd

Nasdaq Pharmaceutical Preparations E9 CIK: 0001704292
AI RATING
SELL
75% Confidence

Investment Thesis

Zai Lab is burning cash (-$13.1M FCF annually) while generating negligible revenue growth (0.7% YoY), with severe operating losses (-69.7% margin) indicating fundamental commercialization challenges. Although the $651.3M cash position and improving loss trends provide some runway, the stalled revenue base and unsustainable cash burn present material risk without demonstrated acceleration.

Strengths

  • + Strong cash position of $651.3M with zero long-term debt provides extended runway
  • + Improving loss trends year-over-year (net loss improved 31.7%) shows operational progress
  • + Solid balance sheet with positive $662M equity and 2.40x current ratio limits liquidity risk

Risks

  • ! Negative free cash flow of -$13.1M with essentially flat revenue growth (0.7%) demonstrates unsustainable unit economics
  • ! Severe operating losses of -$69.4M on $99.6M revenue (-69.7% margin) with no clear profitability timeline
  • ! Stalled revenue growth and negative operating cash flow suggest pipeline commercialization failures or market adoption challenges

Key Metrics to Watch

Financial Metrics

Revenue
99.6M
Net Income
-51.0M
EPS (Diluted)
$-0.05
Free Cash Flow
-13.1M
Total Assets
1.1B
Cash
651.3M

Profitability Ratios

Gross Margin N/A
Operating Margin -69.7%
Net Margin -51.2%
ROE -7.7%
ROA -4.7%
FCF Margin -13.2%

Balance Sheet & Liquidity

Current Ratio
2.40x
Quick Ratio
2.19x
Debt/Equity
0.00x
Debt/Assets
39.6%
Interest Coverage
-30.78x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-09T14:05:38.931331 | Data as of: 2026-03-31 | Powered by Claude AI